Psoriasis Clinical Trial
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Summary
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
Eligibility Criteria
Inclusion Criteria:
Are 18 years or older with diagnosis for at least 12 months of moderate to severe plaque psoriasis covering as least 10%of body surface area
a Psoriasis Area and Severity Index (PASI) score of 12 and are considered to be candidates for systemic or light therapy
No evidence of active or latent tuberculosis
Exclusion Criteria:
Non-plaque or drug induced forms of psoriasis
cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB)
any uncontrolled significant medical condition
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 66 Locations for this study
Birmingham Alabama, 35209, United States
Irvine California, 92697, United States
San Diego California, 92117, United States
Santa Monica California, 90404, United States
Denver Colorado, 80209, United States
New Haven Connecticut, 06511, United States
Ocala Florida, 34471, United States
Tampa Florida, 33609, United States
Alpharetta Georgia, 30022, United States
Atlanta Georgia, 30327, United States
Newnan Georgia, 30263, United States
Springfield Illinois, 62702, United States
Indianapolis Indiana, 46256, United States
Boston Massachusetts, 02111, United States
Boston Massachusetts, 02114, United States
Omaha Nebraska, 68144, United States
New York New York, 10016, United States
Rochester New York, 14623, United States
Raleigh North Carolina, 27612, United States
Raleigh North Carolina, 27612, United States
Norman Oklahoma, 73071, United States
Lake Oswego Oregon, 97035, United States
Pittsburgh Pennsylvania, 15213, United States
Johnston Rhode Island, 02919, United States
Knoxville Tennessee, 37917, United States
Dallas Texas, 75231, United States
Dallas Texas, 75246, United States
Houston Texas, 77030, United States
Spokane Washington, 99202, United States
Spokane Washington, 99202, United States
Wenatchee Washington, 98801, United States
Madison Wisconsin, 53719, United States
Winnipeg Manitoba, R3C 1, Canada
St. John's Newfoundland and Labrador, A1B 4, Canada
Halifax Nova Scotia, B3H 1, Canada
Barrie Ontario, L4M 6, Canada
Markham Ontario, L3P 1, Canada
North Bay Ontario, P1B 3, Canada
Oakville Ontario, L6J 7, Canada
Ottawa Ontario, K2G 6, Canada
Waterloo Ontario, N2J 1, Canada
Quebec , G1J 1, Canada
Barranquilla Atlantico, 0000, Colombia
Bogot Cundinamarca, 0000, Colombia
Berlin , 10117, Germany
Berlin , 13055, Germany
Bonn , 53105, Germany
Dresden , 01307, Germany
Hamburg , 20253, Germany
Kiel , 24105, Germany
Muenster , 48149, Germany
Schwerin , 19055, Germany
Vechta , 49377, Germany
Wuppertal , 42275, Germany
Kecskemet , 6000, Hungary
Nyiregyhaza , 4400, Hungary
Pecs , 7624, Hungary
Maebashi-shi Gunma, , Japan
Sapporo Hokkaido, , Japan
Chuo-ku Kobe, , Japan
Kumamoto-shi Kumamoto, , Japan
Shinjyuku-ku Tokyo, , Japan
Monterrey Nuevo Leon, 64460, Mexico
Poznan , 60-77, Poland
Szczecin , 70-11, Poland
Wroclaw , 50-36, Poland
Wroclaw , 51-12, Poland
Belgrade , 11000, Serbia
Tainan , 704, Taiwan
Taipei , 110, Taiwan
Simferopol Crimea, 95006, Ukraine
Kharkiv , 61057, Ukraine
Kyiv , 01032, Ukraine
Ternopil , 46006, Ukraine
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.